Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces updated phase III Vectibix data

Amgen announces updated phase III Vectibix data

3rd June 2008

Amgen has announced updated data from two phase III trials assessing Vectibix (panitumumab) used in combination with standard chemotherapy as a treatment in earlier lines of metastatic colorectal cancer (mCRC).

The Prime study is a phase III trial investigating the use of Vectibix in combination with Folfox chemotherapy as a first-line mCRC treatment, while the 20050181 study is assessing the use of the compound in conjunction with Folfiri chemotherapy as as second-line mCRC treatment according to KRAS mutational status.

Meanwhile, the single-arm Precept study was designed to evaluate the efficacy of Vectibix with Folfiri according to Kras status in patients with metastatic disease that has progressed following treatment with an oxaliplatin-based chemotherapy regimen plus bevacizumab.

Roger M Perlmutter, executive vice-president of research and development at Amgen, said: “The data being generated from a number of our ongoing trials in various settings of colorectal cancer continue to inform us about the safety of Vectibix in combination with standard chemotherapy.”

He added that the data regarding the importance of the KRAS mutation underlined the significance of this biomarker in the development of customised treatments for this indication.

Amgen recently announced results from trials of recombinant human Apo2L/TRAIL, AMG 479, AMG 102 and motesanib alone and in combination with chemotherapy or other targeted agents at the annual meeting of the American Society of Clinical Oncology.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.